Analysts Bullish on Boston Scientific (BSX) Amid Expectations for 30% YoY Growth in 2026

Boston Scientific Corporation (NYSE:BSX) is included in our list of the best low-risk high-reward stocks.

Analysts Bullish on Boston Scientific (BSX) Amid Expectations for 30% YoY Growth in 2026

As part of the firm’s Q1 preview for medical technology and life science tools firms, Evercore ISI analyst Vijay Kumar reduced the firm’s price target on Boston Scientific Corporation (NYSE:BSX) to $80 from $96 on April 6, 2026, while maintaining an “Outperform” rating.

On March 30, 2026, following the release of the firm’s clinical trial data, RBC Capital reaffirmed an “Outperform” rating and a $115 price target for Boston Scientific. The firm expects 30% year-over-year growth in 2026, 10 percentage points higher than management guidance. Thus, Boston Scientific remains a good stock to buy.

Meanwhile, the company’s AsurysTM Fluid Management System came into the spotlight recently.

The system, intended to enhance irrigation and regulate intrarenal pressure during urologic procedures like ureteroscopy, received 510(k) clearance from the U.S. Food and Drug Administration. Boston Scientific Corporation (NYSE:BSX) announced this on the same day as RBC Capital’s update.

Based on Boston Scientific Corporation (NYSE:BSX)’s pressure data, the system may control fluid flow in real time, thereby reducing problems and enhancing workflow efficiency and physician visualization. It also allows scope-based irrigation control and integrated pressure monitoring when used with the LithoVue Elite ureteroscope.

Despite more cautious near-term analyst views, the launch expands Boston Scientific’s StoneSmart portfolio.

Boston Scientific Corporation (NYSE:BSX) is a global medical technology leader that develops, manufactures, and markets less-invasive medical devices used in interventional specialties, including cardiology, peripheral interventions, electrophysiology, endoscopy, and urology. Their products, such as stents, pacemakers, and imaging systems, are used by healthcare professionals worldwide to diagnose and treat various diseases.

While we acknowledge the risk and potential of BSX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BSX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.